New discovery links circular DNA by-products to childhood leukaemia relapse
The new paper reveals for the first time that these DNA fragments can persist in cancer cells and may drive relapse in patients with...
Sep 30
Finding a clue to the origin of treatment-resistant leukemia in kids
Chemotherapy resistance is particularly common in what is known as T-ALL, a subtype of ALL. This recent study shows that the origin of...
Sep 26
Premature immune aging occurs in children with leukemia
As we age, some populations of immune cells change in abundance and these changes can be measured and used to infer one’s immunological...
Sep 16
Planned C-Sections Linked to Higher Risk of Cancer in Children
Planned caesarean births—"C-sections"—slightly raise the risk of some childhood cancers—particularly acute lymphoblastic leukemia (ALL),...
Sep 5
Timepoint at which developing B-cells become cancerous impacts leukemia treatment
Scientists at St. Jude Children’s Research Hospital and University Health Network showed that the stage of B-cell development at which...
Sep 4
Targeting fusion protein’s role in childhood leukemia produces striking results
Investigators have discovered how NUP98-fusion proteins drive pediatric acute myeloid leukemia, identifying novel single-agent and...
Aug 29
Potential new treatment to tackle commonest form of childhood cancer
A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukaemia...
Jul 30
Duration of Overweight/Obesity During Treatment Linked to Worse Outcomes in Pediatric Leukemia Patients
New research on children diagnosed with acute lymphoblastic leukemia (ALL) shows that the longer a patient’s body mass index (BMI) falls...
Jul 24
LLS Expands its Global Master Trial for Hard-To-Treat Leukemias in Children
The Leukemia & Lymphoma Society (LLS) announced today the first pediatric patient has received treatment in a new subtrial of its...
Jun 27
Unmasking a hidden threat for optimal ALL treatment in children
Asparaginase (ASNase) remains a cornerstone of chemo regimens for ALL. But there’s a quiet threat that’s often missed: hypersensitivity...
Jun 24